君实生物(01877.HK)治疗轻中度新型冠状病毒药物获内地常规批准

阿斯达克财经
Jan 13, 2025

君实生物(01877.HK) (688180.SH) 公布,其控股子公司上海旺实生物医药科技收到国家药监局核准签发的《药品补充申请批准通知书》,氢溴酸氘瑞米德韦片(商品名:民得维,产品代号:VV116/JT001)用于治疗轻中度新型冠状病毒(COVID-19)感染的成年患者的适应症获得国家药监局同意,由附条件批准转为常规批准。研究结果显示,在轻、中度COVID-19患者中,民得维可显著加速症状缓解...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10